SEC Info - Amgen Inc - ‘10-Q’ for 9/30/01

SEC Info℠

Home

Help

Please Sign In

Amgen Inc – ‘10-Q’ for 9/30/01

On: Friday, 10/26/01 · For: 9/30/01 · Accession #: 1021408-1-508839 · File #: 0-12477

  As Of                Filer                Filing    For·On·As Docs:Size              Issuer               Agent

10/26/01  Amgen Inc                         10-Q        9/30/01   11:255K                                   Donnelley R… Fin’l/NY/FA

Quarterly Report — Form 10-Q
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-Q        Quarterly Report                                      25    111K 
 2: EX-10.1     Amended and Restated 1991 Equity Incentive Plan       17     66K 
 3: EX-10.40    Amended and Restated 1997 Special Non-Officer Plan    11     51K 
 4: EX-10.53    Second Amendment to Amgen Retirement Plan              5     22K 
 5: EX-10.54    Second Amendment to Amgen Change of Control Plan       2     11K 
 6: EX-10.55    First Amend to Amgen Supp Retirement Plan              2      8K 
 7: EX-10.56    Agreement With Dr. George Morstyn                     35     95K 
 8: EX-10.57    Promissory Note of Brian McNamee                       4     19K 
 9: EX-10.58    Restricted Stock Purchase Agreement With Richard       4     20K 
                          Nanula                                                 
10: EX-10.59    Restricted Stock Purchase Agreement With Roger         4     19K 
                          Perlmutter                                             
11: EX-99       Factors That May Affect Amgen                          6     26K

10-Q — Quarterly Report
Document Table of Contents

Page	(sequential)	\|	(alphabetic)	Top
			Alternative Formats (Word, et al.) Exhibits and Reports on Form 8-K Financial Statements Index to Exhibits Inventories Legal Proceedings Management's Discussion and Analysis of Financial Condition and Results of Operations Notes to Condensed Consolidated Financial Statements Signatures
1	1st Page - Filing Submission
3	Item 1. Financial Statements
7	Notes to Condensed Consolidated Financial Statements
"	Inventories
13	Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations
19	Item 1. Legal Proceedings
"	Item 6. Exhibits and Reports on Form 8-K
20	Signatures
21	Index to Exhibits

10-Q 1st Page of 25 TOC ↑Top Previous Next ↓Bottom Just 1st
 
 UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
 WASHINGTON D.C. 20549

 FORM 10-Q

(Mark One)                                                                      

[X]  QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934                                                           

For the quarterly period ended September 30, 2001                     

OR

[ ]  TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES        
EXCHANGE ACT OF 1934                                                  

Commission file number 000-12477

AMGEN INC.
(Exact name of registrant as specified in its charter)

                                                        [Enlarge/Download Table]
                                                                                     
                     Delaware                                   95-3540776           
---------------------------------------------------  --------------------------------
          (State or other jurisdiction of                    (I.R.S. Employer        
           incorporation or organization)                   Identification No.)      

 One Amgen Center Drive, Thousand Oaks, California              91320-1799           
---------------------------------------------------  --------------------------------
     (Address of principal executive offices)                   (Zip Code)           

Registrant's telephone number, including area code            (805) 447-1000         

Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was     
required to file such reports), and (2) has been subject to such filing         
requirements for the past 90 days. Yes [X] No [ ]                               

As of September 30, 2001, the registrant had 1,045,511,203 shares of Common     
Stock, $0.0001 par value, outstanding.                                          

10-Q 2nd Page of 25 TOC 1st Previous Next ↓Bottom Just 2nd
AMGEN INC.

INDEX 

                                                                      Page No.

PART I    FINANCIAL INFORMATION                                                 

     Item 1.  Financial Statements................................   3

Condensed Consolidated Statements of                
Operations - three and nine months                  
         ended September 30, 2001 and 2000........................   4

Condensed Consolidated Balance Sheets -             
         September 30, 2001 and December 31, 2000.................   5

Condensed Consolidated Statements of                
Cash Flows - nine months                            
         ended September 30, 2001 and 2000........................   6

Notes to Condensed Consolidated Financial           
         Statements...............................................   7

Item 2.  Management's Discussion and Analysis               
of Financial Condition and Results of     
              Operations..........................................  13

PART II   OTHER INFORMATION                                                     

     Item 1.  Legal Proceedings...................................  19

     Item 6.  Exhibits and Reports on Form 8-K....................  19

     Signatures...................................................  20

     Index to Exhibits............................................  21

2 

10-Q 3rd Page of 25 TOC 1st Previous Next ↓Bottom Just 3rd
PART I - FINANCIAL INFORMATION

Item 1.  Financial Statements                                                   

    The information in this report for the three and nine months ended
September 30, 2001 and 2000 is unaudited but includes all adjustments           
(consisting only of normal recurring accruals, unless otherwise indicated) which
Amgen Inc. ("Amgen" or the "Company") considers necessary for a fair            
presentation of the results of operations for those periods.                    

   The condensed consolidated financial statements should be read in
conjunction with the Company's financial statements and the notes thereto       
contained in the Company's Annual Report on Form 10-K for the year ended        
December 31, 2000.                                                              

        Interim results are not necessarily indicative of results for the full
fiscal year.                                                                    

 3

10-Q 4th Page of 25 TOC 1st Previous Next ↓Bottom Just 4th
AMGEN INC.
 CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In millions, except per share data)
 (Unaudited)

                                                        [Enlarge/Download Table]

                                                     Three Months Ended        Nine Months Ended     
                                                        September 30,             September 30,      
                                                      2001        2000          2001        2000     
                                                   ----------   ----------  -----------  ----------- 
                                                                                                     
Revenues:                                                                                            
    Product sales                                  $    879.6   $    851.0  $   2,536.9  $   2,355.4 
    Corporate partner revenues                           60.6         51.9        182.0        187.2 
    Royalty income                                       62.9         46.6        172.5        135.4 
                                                   ----------   ----------  -----------  ----------- 
       Total revenues                                 1,003.1        949.5      2,891.4      2,678.0 
                                                   ----------   ----------  -----------  ----------- 

Operating expenses:                                                                                  
    Cost of sales                                       102.7        109.5        290.5        296.9 
    Research and development                            216.9        202.9        632.4        595.5 
    Selling, general and administrative                 221.8        202.9        644.5        577.7 
    Loss of affiliates, net                               5.5          4.8          1.9         26.1 
    Legal award                                             -        (73.9)           -        (73.9)
                                                   ----------   ----------  -----------  ----------- 
       Total operating expenses                         546.9        446.2      1,569.3      1,422.3 
                                                   ----------   ----------  -----------  ----------- 

Operating income                                        456.2        503.3      1,322.1      1,255.7 

Other income (expense):                                                                              
    Interest and other income                            44.4         30.7        133.2        110.3 
    Interest expense, net                                (2.3)        (4.1)       (10.2)       (11.7)
                                                   ----------   ----------  -----------  ----------- 
       Total other income                                42.1         26.6        123.0         98.6 
                                                   ----------   ----------  -----------  ----------- 

Income before income taxes                              498.3        529.9      1,445.1      1,354.3 

Provision for income taxes                              168.4        171.0        488.4        426.6 
                                                   ----------   ----------  -----------  ----------- 
Net income                                         $    329.9   $    358.9  $     956.7  $     927.7 
                                                   ==========   ==========  ===========  =========== 
Earnings per share:                                                                                  
    Basic                                          $     0.31   $     0.35  $      0.92  $      0.90 
    Diluted                                        $     0.30   $     0.33  $      0.88  $      0.86 

Shares used in calculation of earnings per share:                                                    
    Basic                                             1,048.3      1,032.1      1,044.9      1,027.7 
    Diluted                                           1,084.6      1,085.6      1,085.4      1,085.0 

 See accompanying notes.

4 

10-Q 5th Page of 25 TOC 1st Previous Next ↓Bottom Just 5th
AMGEN INC.
 CONDENSED CONSOLIDATED BALANCE SHEETS
(In millions, except per share data)
 (Unaudited)

                                               September 30,    December 31,
                                               2001             2000
                                               -------------   -------------
ASSETS                          
------                          

Current assets:                                                                 
Cash and cash equivalents                       $     284.0     $      226.5  
Marketable securities                               2,145.2          1,801.6  
Trade receivables, net                                481.5            389.2  
Inventories                                           384.4            305.2  
Other current assets                                  187.2            214.6  
                                              -----------     ------------
Total current assets                              3,482.3          2,937.1

Property, plant and equipment at cost, net           1,909.2          1,781.5   
Other assets                                           662.2            681.0   
                                              -----------     ------------
                                              $   6,053.7     $    5,399.6
                                              ===========     ============

LIABILITIES AND STOCKHOLDERS' EQUITY                          
------------------------------------                          
Current liabilities:                                                            
Accounts payable                                $      70.3     $      143.2  
Commercial paper                                      100.0             99.7  
Accrued liabilities                                   552.2            619.2  
                                              -----------     ------------
Total current liabilities                           722.5            862.1

Long-term debt                                         223.0            223.0   

Stockholders' equity:                                                           
Preferred stock; $0.0001 par value; 5.0 shares                                
authorized; none issued or outstanding                   -                - 
Common stock and additional paid-in capital;                                  
$0.0001 par value; 2,750.0 shares authorized;                               
outstanding - 1,045.5 shares in 2001 and                                    
1,037.4 shares in 2000                             3,298.2          2,947.3 
Retained earnings                                   1,773.7          1,304.6  
Accumulated other comprehensive income                 36.3             62.6  
                                              -----------     ------------
Total stockholders' equity                        5,108.2          4,314.5
                                              -----------     ------------

                                              $   6,053.7     $    5,399.6
                                              ===========     ============

 See accompanying notes.

5 

10-Q 6th Page of 25 TOC 1st Previous Next ↓Bottom Just 6th
AMGEN INC.
 CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
 (In millions)
 (Unaudited)

                                                       Nine Months Ended
                                                       September 30,
                                                     2001           2000
                                                     -----------     -----------
Cash flows from operating activities:                                           
Net income                                          $    956.7      $    927.7
Depreciation and amortization                            194.9           156.3
Tax benefits related to employee stock options           166.5           304.5
 Gain on equity investments                               (12.4)          (30.7)
Loss of affiliates, net                                    1.9            26.1
Cash provided by (used in):                                                   
    Trade receivables, net                               (92.3)          108.9
     Inventories                                         (114.3)         (109.3)
     Other current assets                                  (6.4)          (12.9)
    Accounts payable                                     (72.9)           38.2
     Accrued liabilities                                  (67.0)         (145.9)
                                                     -----------     -----------

       Net cash provided by operating activities         954.7         1,262.9
                                                     -----------     -----------

Cash flows from investing activities:                                           
 Purchases of property, plant and equipment              (310.5)         (318.0)
Proceeds from maturities of marketable securities        193.1               -
Proceeds from sales of marketable securities             208.6           868.2
 Purchases of marketable securities                      (701.2)      ( 1,359.7)
 Other                                                     27.4           (15.0)
                                                     -----------     -----------

        Net cash used in investing activities            (582.6)         (824.5)
                                                     -----------     -----------

Cash flows from financing activities:                                           
Net proceeds from issuance of common stock upon the                           
exercise of employee stock options and in                             
    connection with an employee stock purchase plan      181.1           266.1
 Repurchases of common stock                             (487.6)         (645.1)
 Other                                                     (8.1)          (30.5)
                                                     -----------     -----------

        Net cash used in financing activities            (314.6)         (409.5)
                                                     -----------     -----------

Increase in cash and cash equivalents                      57.5            28.9 

Cash and cash equivalents at beginning of period          226.5           130.9 
                                                     -----------     -----------

Cash and cash equivalents at end of period           $    284.0      $    159.8 
                                                     ===========     ===========

 See accompanying notes.

6 

10-Q 7th Page of 25 TOC 1st Previous Next ↓Bottom Just 7th
AMGEN INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2001

1.       Summary of significant accounting policies                             

Business                                                              

         Amgen Inc. ("Amgen" or the "Company") is a global biotechnology company
that discovers, develops, manufactures and markets human therapeutics based on  
advances in cellular and molecular biology.                                     

Principles of consolidation                                           

   The consolidated financial statements include the accounts of the
Company and its wholly owned subsidiaries as well as affiliated companies in    
which the Company has a controlling financial interest and exercises control    
over their operations ("majority controlled affiliates"). All material          
intercompany transactions and balances have been eliminated in consolidation.   
Investments in affiliated companies which are 50% or less owned and where the   
Company exercises significant influence over operations are accounted for using 
the equity method. All other equity investments are accounted for under the cost
method. The caption "Loss of affiliates, net" includes Amgen's equity in the    
operating results of affiliated companies and the minority interest others hold 
in the operating results of Amgen's majority controlled affiliates.             

Inventories                                                           

Inventories are stated at the lower of cost or market. Cost is
determined in a manner which approximates the first-in, first-out (FIFO) method.
Inventories consist of currently marketed products and product candidates which 
the Company expects to commercialize. The inventory balance of such product     
candidates totaled $67.0 million and $112.7 million as of September 30, 2001 and
December 31, 2000, respectively. Inventories are shown net of applicable        
reserves and allowances. Inventories consisted of the following (in millions):  

                                     September 30,    December 31,
                                    2001            2000
                                     -------------    ------------

       Raw materials                 $      34.7      $     29.4
       Work in process                     287.7           238.7
       Finished goods                       62.0            37.1
                                     -------------    ------------
                                     $     384.4      $    305.2
                                     =============    ============

7 

10-Q 8th Page of 25 TOC 1st Previous Next ↓Bottom Just 8th
        The Company has a collaboration agreement with PRAECIS PHARMACEUTICALS
INCORPORATED ("Praecis") relating to the commercialization of abarelix depot    
(now referred to as "Plenaxis(TM)"). Costs of approximately $35 million         
associated with the manufacture of Plenaxis(TM) are no longer classified in     
inventories (see footnote 4 - "Collaboration agreement with Praecis").          

Product sales                                                         

      Product sales primarily consist of sales of EPOGEN(R) (Epoetin alfa)
and NEUPOGEN(R) (Filgrastim).                                                   

        The Company has the exclusive right to sell Epoetin alfa for dialysis,
certain diagnostics and all non-human, non-research uses in the United States.  
The Company sells Epoetin alfa under the brand name EPOGEN(R). Amgen has granted
to Ortho Pharmaceutical Corporation (which has assigned its rights under the    
product license agreement to Ortho Biotech Products, L.P.), a subsidiary of     
Johnson & Johnson ("Johnson & Johnson"), a license relating to Epoetin alfa for 
sales in the United States for all human uses except dialysis and diagnostics.  
Pursuant to this license, the Company and Johnson & Johnson are required to     
compensate each other for Epoetin alfa sales that either party makes into the   
other party's exclusive market, sometimes referred to as "spillover" sales.     
Accordingly, Amgen does not recognize product sales it makes into the exclusive 
market of Johnson & Johnson and does recognize the product sales made by Johnson
& Johnson into Amgen's exclusive market. Sales in Amgen's exclusive market are  
derived from the Company's sales to its customers, as adjusted for any spillover
sales. The Company is employing an audit methodology to measure each party's    
spillover sales based in part on estimates of and subsequent adjustments thereto
of third-party data on shipments to end users and their usage. Sales of the     
Company's other products are recognized when shipped and title has passed.      

Derivative instruments                                                

 The Company adopted Statement of Financial Accounting Standards
("SFAS") No. 133, "Accounting for Derivative Instruments and Hedging            
Activities", as amended, on January 1, 2001 and its adoption has not had a      
material effect on the Company's financial statements. SFAS No. 133 requires    
companies to recognize all of its derivative instruments as either assets or    
liabilities in the balance sheet at fair value. The accounting for changes in   
the fair value (i.e., unrealized gains or losses) of a derivative instrument    
depends on whether it has been designated and qualifies as part of a hedging    
relationship and further, on the type of hedging relationship. Derivatives that 
are not hedges must be adjusted to fair value through current earnings.         

      To protect against possible changes in values of certain anticipated
foreign currency cash flows, primarily resulting from sales outside the U.S.,   
the Company enters into foreign currency forward contracts which qualify and are
designated as cash flow hedges. No portions of these foreign currency forward   
contracts are excluded from the assessment of                                   

8 

10-Q 9th Page of 25 TOC 1st Previous Next ↓Bottom Just 9th
hedge effectiveness, and there are no ineffective portions of these hedging     
instruments. The gains and losses on these forward contracts are reported as a  
component of other comprehensive income and reclassified into earnings in the   
same periods during which the hedged transactions affect earnings. At September 
30, 2001, amounts in accumulated other comprehensive income related to cash flow
hedges were not material.                                                       

   To protect against possible reductions in value of certain of its
available-for-sale marketable equity securities, the Company has entered into   
equity forward contracts which qualify and are designated as fair value hedges. 
The gains and losses on these forward contracts as well as the offsetting losses
and gains on the hedged equity securities are recognized in current earnings.   
During the three and nine months ended September 30, 2001, gains and losses on  
the portions of these forwards excluded from the assessment of hedge            
effectiveness and the ineffective portions of these hedging instruments were not
material.                                                                       

         The Company has additional foreign currency forward contracts to reduce
exposures to foreign currency fluctuations of certain assets and liabilities    
denominated in foreign currencies. However, these contracts have not been       
designated as hedges under SFAS No. 133.                                        

     Prior to the adoption of SFAS No. 133, all of the Company's foreign
exchange forward contracts were adjusted to fair value through current earnings.
Foreign exchange option contracts that hedged anticipated foreign currency      
transactions were deferred and recognized in the same period as the hedged      
transaction. In addition, derivatives that hedged against possible reductions in
the fair values of available-for-sale equity securities were included in the    
basis of the hedged securities and adjusted to fair value through other         
comprehensive income.                                                           

Employee stock option and stock purchase plans                        

  The Company's employee stock option and stock purchase plans are
accounted for under Accounting Principles Board Opinion No. 25, "Accounting for 
Stock Issued to Employees".                                                     

Earnings per share                                                    

       Basic earnings per share is based upon the weighted-average number of
common shares outstanding. Diluted earnings per share is based upon the         
weighted-average number of common shares and dilutive potential common shares   
outstanding. Potential common shares are outstanding options under the Company's
employee stock option plans, restricted stock and potential issuances of stock  
under the employee stock purchase plan (collectively "Dilutive Securities")     
which are included under the treasury stock method.                             

9 

10-Q 10th Page of 25 TOC 1st Previous Next ↓Bottom Just 10th
      The following table sets forth the computation for basic and diluted
earnings per share (in millions, except per share information):                 

                                                        [Enlarge/Download Table]

                                                   Three Months Ended              Nine Months Ended     
                                                      September 30,                  September 30,       
                                                  2001             2000         2001             2000    
                                             ------------      -----------  ------------      -----------
                                                                                                         
Numerator for basic and diluted                                                                          
    earnings per share - net income          $     329.9       $    358.9   $     956.7       $   927.7  
                                             ============      ===========  ============      ===========

Denominator:                                                                                             
    Denominator for basic earnings                                                                       
        per share - weighted-average shares      1,048.3          1,032.1       1,044.9         1,027.7  
    Effect of Dilutive Securities                   36.3             53.5          40.5            57.3  
                                             ------------      -----------  ------------      -----------

    Denominator for diluted earnings                                                                     
       per share - adjusted weighted-                                                                    
       average shares                            1,084.6          1,085.6       1,085.4         1,085.0  
                                             ============      ===========  ============      ===========

Basic earnings per share                     $      0.31       $     0.35   $      0.92       $    0.90  

Diluted earnings per share                   $      0.30       $     0.33   $      0.88       $    0.86  

Recent accounting pronouncements                                      

        In June 2001, the Financial Accounting Standards Board issued SFAS No.
141, "Business Combinations" and SFAS No. 142, "Goodwill and Other Intangible   
Assets" effective for fiscal years beginning after December 15, 2001. Under the 
new rules, goodwill will no longer be amortized but will be subject to annual   
impairment tests in accordance with the statements. Other intangible assets will
continue to be amortized over their useful lives. The Company will apply the new
rules on accounting for goodwill and other intangible assets beginning in the   
first quarter of 2002. Application of the non-amortization provisions of the    
statement is not expected to have a material effect on the Company's financial  
statements. The Company will perform the first of the required impairment tests 
of goodwill as of January 1, 2002 and has not yet determined what the effect of 
these tests will be on the earnings and financial position of the Company.      

Use of estimates                                                      

      The preparation of financial statements in conformity with generally
accepted accounting principles requires management to make estimates and        
assumptions that affect the amounts reported in the financial statements and    
accompanying notes. Actual results may differ from those estimates.             

Basis of presentation                                                 

         The financial information for the three and nine months ended September
30, 2001 and 2000 is unaudited but includes all adjustments (consisting only of 
normal recurring accruals, unless otherwise indicated) which the Company        
considers necessary for a fair presentation of                                  

10

10-Q 11th Page of 25 TOC 1st Previous Next ↓Bottom Just 11th
the results of operations for these periods. Interim results are not necessarily
indicative of results for the full fiscal year.                                 

Reclassification                                                      

     Certain prior year amounts have been reclassified to conform to the
current year presentation.                                                      

2.       Stockholders' equity                                                   

    The Company has a stock repurchase program primarily to reduce the
dilutive effect of its employee stock option and stock purchase plans. Stock    
repurchased under the program is intended to be retired. During the nine months 
ended September 30, 2001, the Company repurchased 8.4 million shares of its     
common stock at a total cost of $487.6 million under its common stock repurchase
program. In December 2000, the Board of Directors authorized the Company to     
repurchase up to $2.0 billion of common stock between January 1, 2001 and       
December 31, 2002. As of September 30, 2001, $1,512.4 million was available     
for stock repurchases through December 31, 2002.                                

3.       Other comprehensive income/(loss)                                      

     SFAS No. 130, "Reporting Comprehensive Income", requires unrealized
gains and losses on the Company's available-for-sale securities, foreign        
currency translation adjustments, and unrealized gains and losses on cash flow  
hedge instruments to be included in other comprehensive income/(loss). During   
the three and nine months ended September 30, 2001, total comprehensive income  
was $307.5 million and $930.4 million, respectively. During the three and nine  
months ended September 30, 2000, total comprehensive income was $393.5 million  
and $1,002.7 million, respectively.                                             

4.       Collaboration agreement with Praecis                                   

        The Company has a collaboration agreement with Praecis relating to the
commercialization of Plenaxis(TM). In September 2001, the Company and Praecis   
announced that they are ending their agreement to jointly develop and           
commercialize Plenaxis(TM) for all indications. Praecis also stated that it     
remains committed to the further development and commercialization of           
Plenaxis(TM). The Company is currently transitioning its development and        
commercialization responsibilities to Praecis and is negotiating various        
financial and other matters related to the termination of this agreement. At    
September 30, 2001, the Company had approximately $60 million of capitalized    
costs related to this agreement                                                 

11

10-Q 12th Page of 25 TOC 1st Previous Next ↓Bottom Just 12th
(including approximately $35 million previously classified as inventories - see 
footnote 1 "Summary of significant accounting policies - Inventories") and will 
incur certain additional costs during the transition period. The Company        
believes it is reasonably possible that it may incur a loss as a result of      
terminating this agreement. However, due to the current status of negotiations  
with Praecis, the Company cannot estimate the amount of such loss, if any.      
Accordingly, no loss has been accrued in the Company's financial statements for 
the three and nine months ended September 30, 2001.                             

12

10-Q 13th Page of 25 TOC 1st Previous Next ↓Bottom Just 13th
Item 2.  Management's Discussion and Analysis of Financial Condition and Results
of Operations                                                 

Liquidity and Capital Resources                                                 

     The Company had cash, cash equivalents and marketable securities of
$2,429.2 million at September 30, 2001, compared with $2,028.1 million at       
December 31, 2000. Cash provided by operating activities has been and is        
expected to continue to be the Company's primary source of funds. During the    
nine months ended September 30, 2001, operations provided $954.7 million of cash
compared with $1,262.9 million during the same period last year.                

       Capital expenditures totaled $310.5 million for the nine months ended
September 30, 2001, compared with $318.0 million for the same period a year ago.
The Company anticipates spending approximately $400 million to $500 million in  
2001 on capital projects and equipment to expand its global operations.         

       The Company receives cash from the exercise of employee stock options
and proceeds from the sale of stock by Amgen pursuant to the employee stock     
purchase plan. During the nine months ended September 30, 2001, employee stock  
option exercises and proceeds from the sale of stock by Amgen pursuant to the   
employee stock purchase plan provided $181.1 million of cash compared with      
$266.1 million for the same period last year. Proceeds from the exercise of     
employee stock options will vary from period to period based upon, among other  
factors, fluctuations in the market value of the Company's stock relative to the
exercise price of such options.                                                 

    The Company has a stock repurchase program primarily to reduce the
dilutive effect of its employee stock option and stock purchase plans. During   
the nine months ended September 30, 2001, the Company purchased 8.4 million     
shares of its common stock at a total cost of $487.6 million compared with 9.9  
million shares purchased at a cost of $645.1 million during the same period last
year. In December 2000, the Board of Directors authorized the Company to        
repurchase up to $2.0 billion of common stock between January 1, 2001 and       
December 31, 2002. The amount the Company spends on and the number of shares    
repurchased each quarter varies based on a variety of factors, including the    
stock price and blackout periods in which the Company is restricted from        
repurchasing shares. As of September 30, 2001, $1,512.4 million was available   
for stock repurchases through December 31, 2002.                                

   To provide for financial flexibility and increased liquidity, the
Company has established several sources of debt financing. As of September 30,  
2001, the Company had $223.0 million of unsecured long-term debt securities     
outstanding. These unsecured long-term debt securities consisted of: 1) $100    
million of debt securities that bear interest at a fixed rate of 6.5% and mature
in 2007 under a $500 million debt shelf registration (the "Shelf"), 2) $100     
million of debt securities that bear interest at a fixed rate of 8.1% and mature
in 2097 and 3) $23 million of debt securities that bear interest at a fixed rate
of 6.2% and mature in 2003. Under the Shelf, all of the remaining $400 million  
of debt securities available for issuance                                       

13

10-Q 14th Page of 25 TOC 1st Previous Next ↓Bottom Just 14th
may be offered under the Company's medium-term note program with terms to be    
determined by market conditions.                                                

         The Company's sources of debt financing also include a commercial paper
program which provides for unsecured short-term borrowings up to an aggregate   
face amount of $200 million. As of September 30, 2001, commercial paper with a  
face amount of $100.0 million was outstanding. These borrowings had maturities  
of less than one month and had effective interest rates averaging 3.1%. In      
addition, the Company has an unsecured $150 million credit facility that expires
on May 28, 2003. This credit facility supports the Company's commercial paper   
program. As of September 30, 2001, no amounts were outstanding under this line  
of credit.                                                                      

   The primary objectives for the Company's investment portfolio are
liquidity and safety of principal. Investments are made to achieve the highest  
rate of return to the Company, consistent with these two objectives. The        
Company's investment policy limits investments to certain types of instruments  
issued by institutions with investment grade credit ratings and places          
restrictions on maturities and concentration by type and issuer.                

The Company believes that existing funds, cash generated from 
operations and existing sources of debt financing are adequate to satisfy its   
working capital and capital expenditure requirements for the foreseeable future,
as well as to support its stock repurchase program. However, the Company may    
raise additional capital from time to time.                                     

Results of Operations                                                           

Product sales                                                         

         Product sales were $879.6 million and $2,536.9 million during the three
and nine months ended September 30, 2001, respectively. These amounts represent 
increases of $28.6 million and $181.5 million, or 3% and 8%, respectively, over 
the same periods last year. Quarterly product sales are influenced by a number  
of factors, including demand, wholesaler inventory management practices and     
foreign exchange effects.                                                       

EPOGEN(R) (Epoetin alfa)/Aranesp(TM) (darbepoetin alfa)       

        In September 2001, the Company received approval to market Aranesp(TM)
in the U.S. for the treatment of anemia associated with chronic renal failure,  
including patients on dialysis and patients not on dialysis. Aranesp(TM) was    
launched in October 2001; thus, there were no U.S. sales in the current year    
quarter. In June 2001, the Company received approval and has launched           
Aranesp(TM) in several countries in the European Union ("EU"). Sales in these EU
markets through September 30, 2001 were not material.                           

  Combined EPOGEN(R) and Aranesp(TM) sales were $519.8 million and
$1,541.3 million for the three and nine months ended September 30, 2001,        
respectively. These                                                             

14

10-Q 15th Page of 25 TOC 1st Previous Next ↓Bottom Just 15th
amounts represent increases of $23.7 million and $111.8 million, or 5% and 8%,  
respectively, over EPOGEN(R) sales in the same periods last year. These         
increases were primarily due to increased EPOGEN(R) demand, which includes the  
effect of higher prices and growth in the U.S. dialysis patient population.     
Sales growth during the three and nine months ended September 30, 2001, was     
negatively impacted to a slight degree by wholesaler inventory changes.         

NEUPOGEN(R) (Filgrastim)                                      

        Worldwide NEUPOGEN(R) sales were $359.8 million and $993.4 million for
the three and nine months ended September 30, 2001, respectively. These amounts 
represent increases of $7.0 million and $80.9 million, or 2% and 9%,            
respectively, over the same periods last year.                                  

         The increase in the three months ended September 30, 2001 was primarily
due to increased worldwide demand, which includes the effect of higher prices in
the U.S. However, this increase was substantially offset by wholesaler inventory
changes, and to a lesser extent, the negative impact of a stronger U.S. dollar. 
The Company believes that demand grew at a high-single digit rate during the    
third quarter. The increase in the nine months ended September 30, 2001 was     
primarily due to worldwide demand growth, which includes the effect of higher   
prices in the U.S., and to a lesser extent, the beneficial effects of wholesaler
inventory changes compared with the prior year period. This increase was        
slightly offset by the negative impact of a stronger U.S. dollar.               

Cost of sales                                                         

        Cost of sales as a percentage of product sales was 11.7% and 11.5% for
the three and nine months ended September 30, 2001, respectively, compared with 
12.9% and 12.6% for the same periods last year. These decreases were primarily  
due to reduced royalty obligations.                                             

Research and development                                              

         During the three and nine months ended September 30, 2001, research and
development expenses increased $14.0 million and $36.9 million, or 7% and 6%,   
respectively, compared with the same periods last year. The increase for the    
three months ended September 30, 2001 was primarily due to higher staff-related 
costs necessary to support ongoing product development activities. The increase 
for the nine months ended September 30, 2001, was due to higher staff-related   
costs, partially offset by lower clinical manufacturing and product             
licensing-related costs.                                                        

Selling, general and administrative                                   

     During the three and nine months ended September 30, 2001, selling,
general and administrative ("SG&A") expenses increased $18.9 million and $66.8  
million, or 9% and 12%, respectively, compared with the same periods last year. 
These increases were primarily due to higher staff-related costs, consulting    
expenses, and outside marketing expenses as the                                 

15

10-Q 16th Page of 25 TOC 1st Previous Next ↓Bottom Just 16th
Company continues to support its existing products and prepares for anticipated 
new product launches.                                                           

Legal award                                                           

        Included in the three months ended September 30, 2000 was a benefit of
$73.9 million primarily from an award for certain costs and expenses, including 
attorneys' fees, associated with the spillover arbitration with Johnson &       
Johnson.                                                                        

Interest and other income                                             

         During the three and nine months ended September 30, 2001, interest and
other income increased $13.7 and $22.9, or 45% and 21%, respectively, over the  
same periods last year. The increase for the three months ended September 30,   
2001 was primarily due to higher interest income generated from the Company's   
investment portfolio as a result of higher average cash balances. The increase  
for the nine months ended September 30, 2001 was primarily due to higher        
interest income generated from the Company's investment portfolio as a result of
higher average cash balances, partially offset by higher gains on the sale of   
equity investments that occurred in the second quarter of 2000.                 

Income taxes                                                          

     The Company's effective tax rate for both the three and nine months
ended September 30, 2001 was 33.8%, compared with 32.3% and 31.5%, respectively,
for the same periods last year. The Company's tax rate has increased primarily  
as a result of increased taxable income combined with a provision in the federal
tax law that caps tax benefits associated with the Company's Puerto Rico        
operations at the 1995 income level.                                            

Financial Outlook                                                               

   In the third quarter, the Company received regulatory approval to
market Aranesp(TM) in the U.S. for the treatment of anemia associated with      
chronic renal failure, including patients on dialysis and patients not on       
dialysis. Aranesp(TM) was launched in the U.S. in October 2001. The Company     
received approval in the second quarter to market Aranesp(TM) in the EU,        
Australia and New Zealand. Aranesp(TM) has been launched in several EU          
countries, and launches in additional countries will occur as reimbursement is  
obtained.                                                                       

       Because the Company is unable to predict the timing and the extent to
which health care providers in the U.S. may transition from administering       
EPOGEN(R) to Aranesp(TM), sales guidance for EPOGEN(R) and Aranesp(TM) is       
provided on a combined basis. The Company continues to expect 2001 combined     
EPOGEN(R) and Aranesp(TM) sales to grow at a low-double digit rate over 2000    
EPOGEN(R) sales. In the future, the Company expects the growth of its anemia    
business to be driven primarily by Aranesp(TM) sales in new market              

16

10-Q 17th Page of 25 TOC 1st Previous Next ↓Bottom Just 17th
opportunities. The Company expects growth in its U.S. dialysis business to come 
primarily from patient population growth and inflation-related price increases. 
Patients receiving treatment for end stage renal disease are covered primarily  
under medical programs provided by the federal government. Therefore, EPOGEN(R) 
sales may also be affected by future changes in reimbursement rates or a change 
in the basis for reimbursement by the federal government. Worldwide Aranesp(TM) 
sales will be dependent in part upon such factors as the effects of competitive 
pressures, penetration of existing and new market opportunities, and the        
availability and extent of reimbursement by third party payors including        
governments and private insurance plans.                                        

         In 2001, the Company continues to expect NEUPOGEN(R) sales growth to be
in the high-single digits. Future NEUPOGEN(R) demand is dependent primarily upon
penetration of existing markets and the effects of competitive products. In     
addition, chemotherapy treatments that are less myelosuppressive may require    
less NEUPOGEN(R). NEUPOGEN(R) usage is expected to continue to be affected by   
cost containment pressures from governments and private insurers on health care 
providers worldwide. In addition, reported NEUPOGEN(R) sales will continue to be
affected by changes in foreign currency exchange rates. In both domestic and    
foreign markets, sales of NEUPOGEN(R) are dependent, in part, on the            
availability of reimbursement from third party payors such as governments (for  
example, Medicare and Medicaid programs in the U.S.) and private insurance      
plans. Therefore, NEUPOGEN(R) sales may also be affected by future changes in   
reimbursement rates or changes in the bases for reimbursement.                  

       The Company continues to expect 2001 total product sales and earnings
per share, excluding non-recurring items, to grow at low-double digit rates. In 
2001, corporate partner revenues are expected to be less than 2000 revenues,    
cost of sales is estimated to be in the range of 11% to 12% of total product    
sales, research and development expenses and SG&A expenses are each estimated to
be in the range of 25% to 27% of total product sales, and the effective tax rate
is expected to be approximately 34%.                                            

      For information regarding the commercialization of Plenaxis(TM), see
footnote 4 - "Collaboration agreement with Praecis" to the condensed            
consolidated financial statements.                                              

        Estimates of future product sales, operating expenses and earnings per
share are necessarily speculative in nature and are difficult to predict with   
accuracy. The Company is providing this information as of the filing date of    
this Form 10-Q, and does not plan to update this information and expressly      
disclaims any duty to update the information contained in this filing.          

     Except for the historical information contained herein, the matters
discussed herein are by their nature forward-looking. Investors are cautioned   
that forward-looking statements or projections made by the Company, including   
those made in this document, are subject to risks and uncertainties that may    
cause actual results to differ materially from those projected. Reference is    
made in particular to forward-looking statements regarding product sales,       
earnings per share and expenses. Amgen operates in a rapidly changing           
environment                                                                     

17

10-Q 18th Page of 25 TOC 1st Previous Next ↓Bottom Just 18th
that involves a number of risks, some of which are beyond the Company's control.
Future operating results and the Company's stock price may be affected by a     
number of factors, including, without limitation: (i) the results of preclinical
and clinical trials; (ii) regulatory approvals of product candidates, new       
indications and manufacturing facilities; (iii) health care guidelines and      
policies relating to Amgen's products; (iv) reimbursement for Amgen's products  
by governments and private payors; (v) intellectual property matters (patents)  
and the results of litigation; (vi) competition; (vii) fluctuations in operating
results and (viii) rapid growth of the Company. These factors and others are    
discussed herein and in Exhibit 99 filed with this report titled "Factors That  
May Affect Amgen" and incorporated herein by reference.                         

18

10-Q 19th Page of 25 TOC 1st Previous Next ↓Bottom Just 19th
 PART II - OTHER INFORMATION

Item 1.  Legal Proceedings                                                      

Certain of the Company's legal proceedings are reported in the
Company's Annual Report on Form 10-K for the year ended December 31, 2000, with 
material developments since that report described in the Company's Form 10-Q for
the quarters ended March 31, 2001 and June 30, 2001, and below. While it is not 
possible to predict accurately or to determine the eventual outcome of these    
matters, the Company believes that the outcome of these proceedings will not    
have a material adverse effect on the annual financial statements of the        
Company.                                                                        

Johnson & Johnson arbitrations                                                  

The trial date is scheduled for January 2002.                 

Genentech litigation                                                            

       Briefing was completed and the Federal Circuit Court of Appeals heard
oral arguments in October 2001.                                                 

Biogen litigation                                                               

    The Massachusetts District Court had set September 12, 2001 as the
hearing date for Amgen's contention that prosecution history estoppel and issue 
preclusion compel findings of non-infringement of the '642 and '658 patents in  
the NEUPOGEN(R) action and the dismissal of the INFERGEN(R) action. Due to the  
events of September 11, 2001, the hearing was rescheduled to December 19, 2001. 

Item 6.  Exhibits and Reports on Form 8-K                                       

     (a)     Reference is made to the Index to Exhibits included herein.

(b)     Reports on Form 8-K - none                            

19

10-Q 20th Page of 25 TOC 1st Previous Next ↓Bottom Just 20th
SIGNATURES

      Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the    
undersigned thereunto duly authorized.                                          

      Amgen Inc.
        (Registrant)

Date:      10/26/01                   By:  /s/  Richard D. Nanula               
---------------------------           ------------------------------------------
                                 Richard D. Nanula
                                    Executive Vice President, Finance,
                                  Strategy and Communications,
                                 and Chief Financial Officer

Date:      10/26/01                   By:   /s/  Barry D. Schehr                
---------------------------           ------------------------------------------
                                 Barry D. Schehr
                                   Vice President, Financial Operations,
                                  and Chief Accounting Officer

20

10-Q 21st Page of 25 TOC 1st Previous Next ↓Bottom Just 21st
AMGEN INC.

 INDEX TO EXHIBITS

Exhibit No.                           Description                               

3.1        Restated Certificate of Incorporation as amended. (10)         
  3.2        Amended and Restated Bylaws of Amgen Inc. (as amended October 24,
2000). (20)                                         
   3.3        Certificate of Amendment of Restated Certificate of Incorporation.
(19)                                                
3.4        Certificate of Designations of Series A Junior Participating   
Preferred Stock. (22)                               
 4.1        Indenture dated January 1, 1992 between the Company and Citibank
N.A., as trustee. (4)                               
   4.2        First Supplement to Indenture, dated February 26, 1997 between the
Company and Citibank N.A., as trustee. (7)          
4.3        Officer's Certificate pursuant to Sections 2.1 and 2.3 of the  
           Indenture, as supplemented, establishing a series of securities
"8-1/8% Debentures due April 1, 2097." (9)          
4.4        8-1/8% Debentures due April 1, 2097. (9)                       
 4.5        Form of stock certificate for the common stock, par value $.0001
of the Company. (10)                                
4.6        Officer's Certificate pursuant to Sections 2.1 and 2.3 of the  
          Indenture, dated as of January 1, 1992, as supplemented by the
             First supplemental Indenture, dated as of February 26, 1997, each
              between the Company and Citibank, N.A., as Trustee, establishing a
             series of securities entitled "6.50% Notes Due December 1, 2007".
(12)                                                
4.7        6.50% Notes Due December 1, 2007 described in Exhibit 4.6. (12)
 4.8        Corporate Commercial Paper - Master Note between and among Amgen
           Inc., as Issuer, Cede & Co., as nominee of The Depository Trust
Company and Citibank, N.A. as Paying Agent. (14)    
10.1*       Company's Amended and Restated 1991 Equity Incentive Plan.      
10.2        Company's Amended and Restated 1997 Special Non-Officer Equity  
Incentive Plan. (22)                                
 10.3        Shareholder's Agreement of Kirin-Amgen, Inc., dated May 11, 1984,
        between the Company and Kirin Brewery Company, Limited. (22)
10.4        Amendment Nos. 1, 2, and 3, dated March 19, 1985, July 29, 1985 
     and December 19, 1985, respectively, to the Shareholder's
    Agreement of Kirin-Amgen, Inc., dated May 11, 1984. (19)
10.5        Product License Agreement, dated September 30, 1985, and        
           Technology License Agreement, dated, September 30, 1985 between
  the Company and Ortho Pharmaceutical Corporation. (19)

21

10-Q 22nd Page of 25 TOC 1st Previous Next ↓Bottom Just 22nd
10.6       Product License Agreement, dated September 30, 1985, and       
          Technology License Agreement, dated September 30, 1985 between
        Kirin-Amgen, Inc. and Ortho Pharmaceutical Corporation. (19)
  10.7       Company's Amended and Restated Employee Stock Purchase Plan. (19)
  10.8       Research, Development Technology Disclosure and License Agreement
             PPO, dated January 20, 1986, by and between the Company and Kirin
Brewery Co., Ltd. (1)                               
  10.9       Amendment Nos. 4 and 5, dated October 16, 1986 (effective July 1,
              1986) and December 6, 1986 (effective July 1, 1986), respectively,
            to the Shareholders Agreement of Kirin-Amgen, Inc. dated May 11,
1984. (22)                                          
 10.10       Assignment and License Agreement, dated October 16, 1986, between
the Company and Kirin-Amgen, Inc. (22)              
  10.11       G-CSF European License Agreement, dated December 30, 1986, between
Kirin-Amgen, Inc. and the Company. (22)             
10.12       Company's Retirement and Savings Plan (as amended and restated  
effective October 23, 2000). (22)                   
10.13       Company's Amended and Restated 1988 Stock Option Plan. (6)      
10.14       First Amendment to the Company's Retirement and Savings Plan (as
  amended and restated effective October 23, 2000). (22)
10.15       Amendment, dated June 30, 1988, to Research, Development,       
           Technology Disclosure and License Agreement: GM-CSF dated March
             31, 1987, between Kirin Brewery Company, Limited and the Company.
(2)                                                 
  10.16       Agreement on G-CSF in Certain European Countries, dated January 1,
           1989, between Amgen Inc. and F. Hoffmann-La Roche & Co. Limited
              Company (with certain confidential information deleted therefrom).
(3)                                                 
 10.17       Partnership Purchase Agreement, dated March 12, 1993, between the
     Company, Amgen Clinical Partners, L.P., Amgen Development
             Corporation, the Class A limited partners and the Class B limited
partner. (5)                                        
10.18       Amgen Inc. Supplemental Retirement Plan (As Amended and Restated
Effective November 1, 1999). (18)                   
10.19       First Amendment to Amgen Inc. Change of Control Severance Plan. 
(19)                                                
 10.20       Amended and Restated Amgen Performance Based Management Incentive
Plan. (17)                                          
 10.21       Credit Agreement, dated as of May 28, 1998, among Amgen Inc., the
          Borrowing Subsidiaries named therein, the Banks named therein,
       Citibank, N.A., as Issuing Bank, and Citicorp USA, Inc., as
Administrative Agent. (15)                          
10.22       G-CSF United States License Agreement dated June 1, 1987        
      (effective July 1, 1986) between Kirin-Amgen, Inc. and the
Company. (22)                                       
 10.23       Amendment No. 1 dated October 20, 1988 to Kirin-Amgen, Inc./Amgen
    G-CSF United States License Agreement dated June 1, 1987
(effective July 1, 1986). (22)                      
10.24       Amendment No. 2 dated October 17, 1991 (effective November 13,  
        1990) to Kirin-Amgen, Inc./Amgen G-CSF United States License
       Agreement dated June 1, 1987 (effective July 1, 1986). (22)

22

10-Q 23rd Page of 25 TOC 1st Previous Next ↓Bottom Just 23rd
10.25       Amendment No. 10 dated March 1, 1996 to the Shareholders'       
   Agreement of Kirin-Amgen, Inc. dated May 11, 1984. (22)
10.26       Amgen Inc. Change of Control Severance Plan effective as of     
October 20, 1998. (16)                              
10.27       Preferred Share Rights Agreement, dated as of December 12, 2000,
             between Amgen Inc. and American Stock Transfer and Trust Company,
as Rights Agent. (21)                               
10.28       First Amendment, effective January 1, 1998, to the Company's    
   Amended and Restated Employee Stock Purchase Plan. (11)
10.29       Amendment No. 11 dated March 20, 2000 to the Shareholders'      
   Agreement of Kirin-Amgen, Inc. dated May 11, 1984. (22)
  10.30       Agreement between Amgen Inc. and Dr. Fabrizio Bonanni, dated March
3, 1999. (18)                                       
10.31       Amendment No. 1 dated June 1, 1987 to Kirin-Amgen, Inc./Amgen   
          G-CSF European License Agreement dated December 30, 1986. (22)
10.32       Amendment No. 2 dated March 15, 1988 to Kirin-Amgen, Inc./Amgen 
          G-CSF European License Agreement dated December 30, 1986. (22)
 10.33       Amendment No. 3 dated October 20, 1988 to Kirin-Amgen, Inc./Amgen
          G-CSF European License Agreement dated December 30, 1986. (22)
  10.34       Amendment No. 4 dated December 29, 1989 to Kirin-Amgen, Inc./Amgen
          G-CSF European License Agreement dated December 30, 1986. (22)
 10.35       Company's Amended and Restated 1987 Directors' Stock Option Plan.
(8)                                                 
10.36       Amended and Restated Agreement on G-CSF in the EU between Amgen 
        Inc. and F. Hoffmann-La Roche Ltd (with certain confidential
information deleted therefrom). (14)                
10.37       Collaboration and License Agreement, dated December 15, 1997,   
    between the Company, GPI NIL Holdings, Inc. and Guilford
       Pharmaceuticals Inc. (with certain confidential information
deleted therefrom). (13)                            
10.38       Promissory Note of Dr. Fabrizio Bonanni, dated August 7, 1999.  
(18)                                                
10.39       Promissory Note of Dr. Fabrizio Bonanni, dated October 29, 1999.
(18)                                                
10.40*      Company's Amended and Restated 1997 Equity Incentive Plan.      
10.41       Agreement between Amgen Inc. and Mr. Gordon M. Binder, dated May
10, 2000. (19)                                      
 10.42       Amendment No. 6 dated May 11, 1984 to the Shareholders' Agreement
of Kirin-Amgen, Inc. dated May 11, 1984. (22)       
10.43       Amendment No. 7 dated July 17, 1987 (effective April 1, 1987) to
          the Shareholders' Agreement of Kirin-Amgen, Inc. dated May 11,
1984. (22)                                          
10.44       Amendment No. 8 dated May 28, 1993 (effective November 13, 1990)
             to the Shareholders' Agreement of Kirin-Amgen, Inc. dated May 11,
1984. (22)                                          
10.45       Amendment No. 9 dated December 9, 1994 (effective June 14, 1994)
             to the Shareholders' Agreement of Kirin-Amgen, Inc. dated May 11,
1984. (22)                                          
  10.46       Agreement between Amgen Inc. and Mr. George J. Morrow, dated March
3, 2001. (23)                                       
10.47       Promissory Note of Mr. George J. Morrow, dated March 11, 2001.  
(23)                                                

23

10-Q 24th Page of 25 TOC 1st Previous Next ↓Bottom Just 24th
10.48      Agreement between Amgen Inc. and Dr. Roger M. Perlmutter, M.D.,
Ph.D., dated March 5, 2001. (23)                    
 10.49      Agreement between Amgen Inc. and Mr. Brian McNamee, dated May 5,
2001. (24)                                          
   10.50      Agreement between Amgen Inc. and Mr. Richard Nanula, dated May 15,
2001. (24)                                          
 10.51      Promissory Note of Mr. Richard Nanula, dated June 27, 2001. (24)
 10.52      Promissory Note of Dr. Roger M. Perlmutter, dated June 29, 2001.
(24)                                                
10.53*     Second Amendment to the Amgen Retirement and Savings Plan as   
amended and restated effective October 15, 2001.    
10.54*     Second Amendment to the Amgen Inc. Change of Control Severance 
Plan.                                               
10.55*     First Amendment to the Amgen Supplemental Retirement Plan as   
amended and restated effective November 1, 1999.    
10.56*     Agreement between Amgen Inc. and Dr. George Morstyn, dated July
19, 2001.                                           
10.57*     Promissory Note of Mr. Brian McNamee, dated May 30, 2001.      
10.58*     Restricted Stock Purchase Agreement between Amgen Inc. and Mr. 
Richard Nanula, dated May 16, 2001.                 
10.59*     Restricted Stock Purchase Agreement between Amgen Inc. and Dr. 
Roger M. Perlmutter, dated January 8, 2001.         
99*        "Factors That May Affect Amgen"                                

___________________                                                             
*    Filed herewith.                                                          

(1)   Filed as an exhibit to Amendment No. 1 to Form S-1 Registration Statement 
   (Registration No. 33-3069) on March 11, 1986 and incorporated herein by
reference.                                                          
(2)   Filed as an exhibit to Form 8 amending the Quarterly Report on Form 10-Q  
   for the quarter ended June 30, 1988 on August 25, 1988 and incorporated
herein by reference.                                                
(3)   Filed as an exhibit to the Form 8 dated November 8, 1989, amending the    
    Annual Report on Form 10-K for the year ended March 31, 1989 on June 28,
1989 and incorporated herein by reference.                          
(4)   Filed as an exhibit to Form S-3 Registration Statement dated December 19, 
1991 and incorporated herein by reference.                          
(5)   Filed as an exhibit to the Form 8-A dated March 31, 1993 and incorporated 
herein by reference.                                                
(6)   Filed as an exhibit to the Form 10-Q for the quarter ended September 30,  
1996 on November 5, 1996 and incorporated herein by reference.      
(7)   Filed as an exhibit to the Form 8-K Current Report dated March 14, 1997 on
March 14, 1997 and incorporated herein by reference.                
(8)   Filed as an exhibit to the Annual Report on Form 10-K for the year ended  
     December 31, 1996 on March 24, 1997 and incorporated herein by reference.
(9)   Filed as an exhibit to the Form 8-K Current Report dated April 8, 1997 on 
April 8, 1997 and incorporated herein by reference.                 
(10)  Filed as an exhibit to the Form 10-Q for the quarter ended March 31, 1997 
on May 13, 1997 and incorporated herein by reference.               

24

10-Q Last Page of 25 TOC 1st Previous Next ↓Bottom Just 25th
(11)  Filed as an exhibit to the Form 10-Q for the quarter ended June 30, 1997  
on August 12, 1997 and incorporated herein by reference.            
(12)  Filed as an exhibit to the Form 8-K Current Report dated and filed on     
December 5, 1997 and incorporated herein by reference.              
(13)  Filed as Exhibit 10.40 to the Guilford Pharmaceuticals Inc. Form 10-K for 
      the year ended December 31, 1997 on March 27, 1998 and incorporated herein
by reference.                                                       
(14)  Filed as an exhibit to the Form 10-Q for the quarter ended March 31, 1998 
on May 13, 1998 and incorporated herein by reference.               
(15)  Filed as an exhibit to the Form 10-Q for the quarter ended June 30, 1998  
on August 14, 1998 and incorporated herein by reference.            
(16)  Filed as an exhibit to the Annual Report on Form 10-K for the year ended  
     December 31, 1998 on March 16, 1999 and incorporated herein by reference.
(17)  Filed as an exhibit to the Form 10-Q for the quarter ended June 30, 1999  
on August 3, 1999 and incorporated herein by reference.             
(18)  Filed as an exhibit to the Annual Report on Form 10-K for the year ended  
    December 31, 1999 on March 7, 2000 and incorporated herein by reference.
(19)  Filed as an exhibit to the Form 10-Q for the quarter ended June 30, 2000  
on August 1, 2000 and incorporated herein by reference.             
(20)  Filed as an exhibit to the Form 10-Q for the quarter ended September 30,  
2000 on November 14, 2000 and incorporated herein by reference.     
(21)  Filed as an exhibit to the Form 8-K Current Report dated December 13, 2000
on December 18, 2000 and incorporated herein by reference.          
(22)  Filed as an exhibit to the Annual Report on Form 10-K for the year ended  
    December 31, 2000 on March 7, 2001 and incorporated herein by reference.
(23)  Filed as an exhibit to the Form 10-Q for the quarter ended March 31, 2001 
on May 14, 2001 and incorporated herein by reference.               
(24)  Filed as an exhibit to the Form 10-Q for the quarter ended June 30, 2001  
on July 27, 2001 and incorporated herein by reference.              

25

10-Q	1st Page of 25	TOC	↑Top	Previous	Next	↓Bottom	Just 1st

10-Q	2nd Page of 25	TOC	1st	Previous	Next	↓Bottom	Just 2nd

10-Q	3rd Page of 25	TOC	1st	Previous	Next	↓Bottom	Just 3rd

10-Q	4th Page of 25	TOC	1st	Previous	Next	↓Bottom	Just 4th

10-Q	5th Page of 25	TOC	1st	Previous	Next	↓Bottom	Just 5th

10-Q	6th Page of 25	TOC	1st	Previous	Next	↓Bottom	Just 6th

10-Q	7th Page of 25	TOC	1st	Previous	Next	↓Bottom	Just 7th

10-Q	8th Page of 25	TOC	1st	Previous	Next	↓Bottom	Just 8th

10-Q	9th Page of 25	TOC	1st	Previous	Next	↓Bottom	Just 9th

10-Q	10th Page of 25	TOC	1st	Previous	Next	↓Bottom	Just 10th

10-Q	11th Page of 25	TOC	1st	Previous	Next	↓Bottom	Just 11th

10-Q	12th Page of 25	TOC	1st	Previous	Next	↓Bottom	Just 12th

10-Q	13th Page of 25	TOC	1st	Previous	Next	↓Bottom	Just 13th

10-Q	14th Page of 25	TOC	1st	Previous	Next	↓Bottom	Just 14th

10-Q	15th Page of 25	TOC	1st	Previous	Next	↓Bottom	Just 15th

10-Q	16th Page of 25	TOC	1st	Previous	Next	↓Bottom	Just 16th

10-Q	17th Page of 25	TOC	1st	Previous	Next	↓Bottom	Just 17th

10-Q	18th Page of 25	TOC	1st	Previous	Next	↓Bottom	Just 18th

10-Q	19th Page of 25	TOC	1st	Previous	Next	↓Bottom	Just 19th

10-Q	20th Page of 25	TOC	1st	Previous	Next	↓Bottom	Just 20th

10-Q	21st Page of 25	TOC	1st	Previous	Next	↓Bottom	Just 21st

10-Q	22nd Page of 25	TOC	1st	Previous	Next	↓Bottom	Just 22nd

10-Q	23rd Page of 25	TOC	1st	Previous	Next	↓Bottom	Just 23rd

10-Q	24th Page of 25	TOC	1st	Previous	Next	↓Bottom	Just 24th

10-Q	Last Page of 25	TOC	1st	Previous	Next	↓Bottom	Just 25th

Dates Referenced Herein and Documents Incorporated by Reference

		Referenced-On Page
This ‘10-Q’ Filing	Date	First	Last	Other Filings

	12/1/07	21
	5/28/03	14		3
	12/31/02	11	13	10-K, 11-K, 4
	1/1/02	10
	12/19/01	19
	12/15/01	10
Filed on:	10/26/01
	10/15/01	24
For Period End:	9/30/01	1	16
	9/12/01	19
	9/11/01	19
	7/27/01	25		10-Q
	7/19/01	24
	6/30/01	19	25	10-Q
	6/29/01	24
	6/27/01	24
	5/30/01	24
	5/16/01	24
	5/15/01	24
	5/14/01	25		10-Q
	5/5/01	24
	3/31/01	19	25	10-Q
	3/11/01	23
	3/7/01	25		10-K, S-3, S-8
	3/5/01	24
	3/3/01	23
	1/8/01	24
	1/1/01	8	13
	12/31/00	2	25	10-K, 11-K
	12/18/00	25		8-K
	12/13/00	25		8-K, SC 13D/A
	12/12/00	23
	11/14/00	25		10-Q
	10/24/00	21
	10/23/00	22		SC TO-T/A
	9/30/00	2	25	10-Q
	8/1/00	25		10-Q
	6/30/00	25		10-Q
	5/10/00	23
	3/20/00	23
	3/7/00	25		10-K405, SC 13D/A
	12/31/99	25		10-K405, 11-K
	11/1/99	22	24
	10/29/99	23
	8/7/99	23
	8/3/99	25		10-Q
	6/30/99	25		10-Q
	3/16/99	25		10-K
	3/3/99	23		PRE 14A
	12/31/98	25		10-K
	10/20/98	23
	8/14/98	25		10-Q
	6/30/98	25		10-Q, 10-Q/A
	5/28/98	22
	5/13/98	25		10-Q
	3/31/98	25		10-Q
	3/27/98	25
	1/1/98	23
	12/31/97	25		10-K, 10-K/A
	12/15/97	23
	12/5/97	25		8-K
	8/12/97	25		10-Q
	6/30/97	25		10-Q
	5/13/97	24
	4/8/97	24		8-K
	3/31/97	24		10-Q
	3/24/97	24		10-K
	3/14/97	24		8-K
	2/26/97	21		8-K
	12/31/96	24		10-K
	11/5/96	24		10-Q
	9/30/96	24		10-Q
	3/1/96	23
	12/9/94	23
	6/14/94	23
	5/28/93	23
	3/31/93	24
	3/12/93	22
	1/1/92	21
				List all Filings

↑Top

Filing Submission 0001021408-01-508839 – Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Amgen Inc – ‘10-Q’ for 9/30/01

On: Friday, 10/26/01 · For: 9/30/01 · Accession #: 1021408-1-508839 · File #: 0-12477

Previous ‘10-Q’: ‘10-Q’ on 7/27/01 for 6/30/01 · Next: ‘10-Q’ on 4/29/02 for 3/31/02 · Latest: ‘10-Q’ on 10/31/23 for 9/30/23

Quarterly Report — Form 10-QFiling Table of Contents

10-Q — Quarterly ReportDocument Table of Contents

Dates Referenced Herein and Documents Incorporated by Reference

Quarterly Report — Form 10-Q
Filing Table of Contents

10-Q — Quarterly Report
Document Table of Contents